Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt –
– Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and minimizes the need for onsite support to new accounts –
Related news for (MOTS)
- Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
- 24/7 Market News Snapshot 21 Feb 2024
- Motus GI Bouncing off Its 52-Week Low
- Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract